NEW YORK (GenomeWeb News) — Diamics will supply its molecular-based cancer-diagnostics systems and cervical cancer tools to a Beijing hospital for three years in exchange for at least $22 million, the company said today.
 
Diamics’ C-Map cervical cancer screening system, which is in clinical trials in the US, uses antibodies to identify cell colonies showing dysregulated growth, which could help identify cervical lesions. 
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.